Product
Portfolio

BioVaxys is leveraging its haptenized antigen technology platforms to develop vaccines to potentially treat viral infections such as SARS-CoV-2, human papillomavirus (HPV), cancers such as late-stage ovarian cancer, cervical cancer and melanoma.

COVID-T™ The world’s first low cost, disposable, diagnostic to identify a T-cell immune response to the presence of SARS-CoV-2. 

Because T-cell mediated immunity to SARS-CoV-2 is as important as an antibody  response.

Learn More About Covid-T™